Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154)

Clin Dev Immunol. 2010:2010:473453. doi: 10.1155/2010/473453. Epub 2011 Jan 5.

Abstract

Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P = .02). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / adverse effects
  • Cancer Vaccines / immunology*
  • HLA-A2 Antigen / metabolism
  • Hormones / immunology
  • Humans
  • Hypersensitivity, Delayed / immunology
  • Interferon-gamma / biosynthesis
  • Male
  • Middle Aged
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / adverse effects
  • Peptide Fragments / chemistry
  • Peptide Fragments / immunology*
  • Peptides / administration & dosage
  • Peptides / adverse effects
  • Peptides / chemistry
  • Peptides / immunology*
  • Prostate-Specific Antigen / administration & dosage
  • Prostate-Specific Antigen / adverse effects
  • Prostate-Specific Antigen / chemistry
  • Prostate-Specific Antigen / immunology*
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / therapy*
  • Risk Factors
  • Vaccination

Substances

  • Cancer Vaccines
  • HLA-A2 Antigen
  • Hormones
  • Peptide Fragments
  • Peptides
  • prostate-specific antigen (146-154)
  • Interferon-gamma
  • Prostate-Specific Antigen